Literature DB >> 338408

Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-etide response to intravenous glucagon.

C Hendriksen, O K Faber, J Drejer, C Binder.   

Abstract

In 83 insulin-treated diabetics the influence of the duration of insulin treatment on the prevalence of residual insulin secretion was examined by determining the plasma C-peptide concentration before and after intravenous injection of 1 mg of glucagon. In 64 patients, plasma C-etide concentration was also determined before and after a standard meal. There was a good correlation between the C-peptide response to glucagon and to the meal (r = 0.67; p less than 0.0001) suggesting that the glucagon test will predict the B-cell response during everyday life. The predictive value of a positive glucagon test was 84% and of a negative test 100%. A preserved, but reduced, B-cell function was demonstrable in 36 of 83 patients. Residual B-cell function was most frequent in the patients with the shortest duration of diabetes. The metabolic importance of endogenous insulin was demonstrated by the significantly lower insulin requirement in the patients with residual B-cell function.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 338408     DOI: 10.1007/bf01236316

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  9 in total

1.  Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood.

Authors:  D L Horwitz; J I Starr; M E Mako; W G Blackard; A H Rubenstein
Journal:  J Clin Invest       Date:  1975-06       Impact factor: 14.808

2.  B-cell function and blood glucose control in insulin dependent diabetics within the first month of insulin treatment.

Authors:  O K Faber; C Binder
Journal:  Diabetologia       Date:  1977-05       Impact factor: 10.122

3.  Radioimmunological determination of human C-peptide in serum.

Authors:  L G Heding
Journal:  Diabetologia       Date:  1975-12       Impact factor: 10.122

4.  C-peptide in children with juvenile diabetes. A preliminary report.

Authors:  J Ludvigsson; L G Heding
Journal:  Diabetologia       Date:  1976-12       Impact factor: 10.122

5.  C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus.

Authors:  O K Faber; C Binder
Journal:  Diabetes       Date:  1977-07       Impact factor: 9.461

6.  Human C-peptide. Part II: Clinical studies.

Authors:  W Beischer; E Heinze; L Keller; S Raptis; W Kerner; E F Pfeiffer
Journal:  Klin Wochenschr       Date:  1976-08-01

7.  Control of juvenile diabetes mellitus and its relationship to endogenous insulin secretion as measured by C-peptide immunoreactivity.

Authors:  L A Grajwer; R S Pildes; D L Horwitz; A H Rubenstein
Journal:  J Pediatr       Date:  1977-01       Impact factor: 4.406

8.  Production of antisera to synthetic benzyloxycarbonyl-C-peptide of human proinsulin.

Authors:  O K Faber; J Markussen; V K Naithani; C Binder
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1976-06

9.  Identification of proinsulin and C-peptide in human serum by a specific immunoassay.

Authors:  F Melani; A H Rubenstein; P E Oyer; D F Steiner
Journal:  Proc Natl Acad Sci U S A       Date:  1970-09       Impact factor: 11.205

  9 in total
  27 in total

1.  Modern management of the insulin dependent diabetic.

Authors:  R Tattersall
Journal:  Ir J Med Sci       Date:  1979       Impact factor: 1.568

2.  Prevalence of residual B cell function and its metabolic consequences in Type 1 (insulin-dependent) diabetes.

Authors:  S Madsbad
Journal:  Diabetologia       Date:  1983-03       Impact factor: 10.122

3.  Factors affecting and patterns of residual insulin secretion during the first year of type 1 (insulin-dependent) diabetes mellitus in children.

Authors:  E B Sochett; D Daneman; C Clarson; R M Ehrlich
Journal:  Diabetologia       Date:  1987-07       Impact factor: 10.122

4.  C-peptide measurement in the differentiation of type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  H L Katzeff; P J Savage; B Barclay-White; M Nagulesparan; P H Bennett
Journal:  Diabetologia       Date:  1985-05       Impact factor: 10.122

5.  Insulin sensitivity and secretion and adipokine profile in patients with Cushing's disease treated with pasireotide.

Authors:  V Guarnotta; G Pizzolanti; A Ciresi; C Giordano
Journal:  J Endocrinol Invest       Date:  2018-02-02       Impact factor: 4.256

6.  Correlation between fasting serum C-peptide and B cell insulin secretory capacity in diabetes mellitus.

Authors:  P Garcia-Webb; A Bonser; T A Welborn
Journal:  Diabetologia       Date:  1982-04       Impact factor: 10.122

7.  Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes.

Authors:  H J Gjessing; L E Matzen; O K Faber; A Frøland
Journal:  Diabetologia       Date:  1989-05       Impact factor: 10.122

8.  Persistent insulin secretion, assessed by plasma C-peptide estimation in long-term juvenile diabetics with a low insulin requirement.

Authors:  C Eff; O Faber; T Deckert
Journal:  Diabetologia       Date:  1978-09       Impact factor: 10.122

9.  Plasma C-peptide response to arginine in insulin-dependent diabetic subjects.

Authors:  D Giugliano; A S Luyckx; P J Lefebvre
Journal:  J Endocrinol Invest       Date:  1980 Jan-Mar       Impact factor: 4.256

10.  Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients.

Authors:  K S Polonsky; J Licinio-Paixao; B D Given; W Pugh; P Rue; J Galloway; T Karrison; B Frank
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.